On one hand, CDADC1 deficiency enhances the sensitivity of human cancer cells to gemcitabine and decitabine, increasing the antitumor efficacy of gemcitabine in mouse models of pancreatic cancer at a dose equivalent to ~380 mg/m2. This evidence concerns the gene CDADC1 and pancreatic neoplasm.